# The impact of gum disease on the levels of a cardiovascular disease marker in the body

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
21/06/2022		☐ Protocol		
Registration date 08/07/2022	Overall study status Completed	Statistical analysis plan		
		[X] Results		
<b>Last Edited</b> 16/01/2023	<b>Condition category</b> Oral Health	[] Individual participant data		

### Plain English summary of protocol

Background and study aims

The endothelium is a thin membrane that lines the inside of the heart and blood vessels. Endothelial dysfunction is one of the early events in atherosclerosis (the thickening or hardening of the heart arteries). Severe gum disease (periodontitis) is considered to be a contributing risk factor for endothelial dysfunction. High blood concentration of a marker protein called asymmetric dimethylarginine (ADMA), has emerged as a predictor of the risk of cardiovascular disease. Thus, reducing periodontal inflammation might have clinical relevance in cardiovascular disease. Insufficient clinical evidence exists to draw clear conclusions regarding the long-term effects of periodontal disease on endothelial function, and even less evidence is available on ADMA concentration and its relationship with periodontitis. The aim of this study was to evaluate the effects of intensive periodontal treatment in modulating endothelial function via the assessment of plasma ADMA concentration in patients diagnosed with severe periodontitis.

Who can participate?

Adult patients diagnosed with generalized periodontitis

#### What does the study involve?

In this 6-month study, all patients will undergo a complete medical and clinical periodontal examination, laboratory analysis of ADMA, and ultrasound assessment of fibromuscular dysplasia (FMD) of the right brachial artery. After the screening, patients were randomly assigned to receive Intensive Periodontal Treatment or Community-based Periodontal Care. A full examination was carried out at baseline, 3 and 6 months after periodontal treatment.

What are the possible benefits and risks of participating?

There are no risks of participating. Benefits are related to the potential improvement of cardiovascular markers.

Where is the study run from? University of Bari Aldo Moro (Italy)

When is the study starting and how long is it expected to run for? July 2017 to October 2019

Who is funding the study? Investigator initiated and funded

Who is the main contact? Dr Biagio Rapone (Italy) biagio.rapone@uniba.it

# Contact information

### Type(s)

Principal investigator

#### Contact name

Dr Biagio Rapone

### Contact details

Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy 60124 +39 3477619817 biagiorapone79@gmail.com

# Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

Nil known

# Study information

### Scientific Title

The impact of periodontal inflammation on endothelial function assessed by circulating levels of asymmetric dimethylarginine: a single-blinded randomized clinical trial

### Acronym

P.I.ADMA

### Study objectives

Periodontal treatment reduces the concentrations of asymmetric dimethylarginine in patients with a high risk of endothelial dysfunction

# Ethics approval required

### Old ethics approval format

### Ethics approval(s)

Approved 16/01/2018, Albania University Ethics Committee (Albanian University, Rr 'Durresit", Tirane 1001, Albania; +355 (0)686086880; e.quorri@albanianuniversity.edu.al), ref: Nr. 16

### Study design

Single-center single-blinded randomized controlled trial

### Primary study design

Interventional

### Study type(s)

**Treatment** 

### Health condition(s) or problem(s) studied

Generalized periodontitis with no risk for endothelial dysfunction

#### **Interventions**

This was a 6-month, randomized controlled trial, including 140 patients between 41 and 63 years old, diagnosed with severe periodontitis, free from cardiovascular disease (CVD), and traditional cardiovascular risk factors. All patients underwent complete medical and clinical periodontal examination, laboratory analysis of ADMA, and ultrasound assessment of fibromuscular dysplasia (FMD) of the right brachial artery. After the screening, they were randomly assigned to receive intensive periodontal treatment (test group, n = 70) or community-based periodontal care (control group, n = 70). A full examination was carried out at baseline, 3 and 6 months after periodontal treatment.

# Intervention Type

Procedure/Surgery

# Primary outcome(s)

Asymmetric dimethylarginine levels in blood measured by enzyme-linked immunosorbent assay (ELISA, DLD Diagnostika, Hamburg, Germany) at baseline, 3 and 6 months

# Key secondary outcome(s))

- 1. Fibromuscular dysplasia (FMD) of the right brachial artery measured using ultrasound at baseline, 3 and 6 months
- 2. Periodontal indices using a periodontal probe at baseline, 3 and 6 months

# Completion date

10/10/2019

# **Eligibility**

# Key inclusion criteria

- 1. Aged between 41 years old and 63 years old
- 2. Diagnosis of generalized periodontitis

# Participant type(s)

### **Patient**

### Healthy volunteers allowed

No

### Age group

Adult

#### Sex

All

### Total final enrolment

140

### Key exclusion criteria

- 1. Patients presenting with dental implants, orthodontic bands and ulcers
- 2. Patients who received periodontal treatment within 12 months prior to the start of the study
- 3. Patients who received systemic antibiotics within the last 6 months
- 4. Pregnancy or breastfeeding mothers
- 5. History of diabetes or a fasting glucose level greater than 126 mg/dl
- 6. History of cardiovascular disease
- 7. Patients with any systemic disease:
- 7.1. Diabetes mellitus
- 7.2. Cardiovascular disease
- 7.3. Kidney disease
- 7.4. Liver disease
- 7.5. Lung disease
- 8. Patients with cardiovascular risk factors and active smokers were excluded to minimize any confounding effect of conditions that may influence endothelial function

### Date of first enrolment

06/06/2018

### Date of final enrolment

07/12/2018

# Locations

### Countries of recruitment

Albania

# Study participating centre Albania University

Rr "Durrèsit", Tiranè 1001 Tirane Albania 1001

# Sponsor information

# Organisation

University of Bari Aldo Moro

### **ROR**

https://ror.org/027ynra39

# Funder(s)

### Funder type

Other

### Funder Name

Investigator initiated and funded

# **Results and Publications**

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the risk of improper use.

# IPD sharing plan summary

Not expected to be made available

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	18/07/2022	16/01/2023	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes